drugset / Trial / NCT00757393
Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to test the hypothesis that growth hormone, administered daily by subcutaneous injection for 2 years will result in a significantly greater BMD Z-score over optimal standard therapy.
Timeline
- Start
- 2008-09
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 0.05 mg/kg | Subcutaneous |
| Background | Calcium carbonate | Other / unclassified | — | — |
| Background | Vitamin D | Other / unclassified | — | — |